Argent LNG to Unveil Innovative Phase One Site Layout at Gastech 2025, Showcasing 900-Acre Expansion at Port Fourchon
'In LNG, it's location, location, location — and Port Fourchon delivers all three, Inside the port means zero drayage, direct deepwater access, and the fastest routes to key markets. '— Jonathan Bass, Chairman & CEO
METAIRIE, LA, UNITED STATES, August 11, 2025 / EINPresswire.com / -- Argent LNG is set to make a powerful entrance at Gastech 2025, unveiling an innovative new site layout for its flagship 25 million tonnes per annum (MTPA) export terminal — launching the first phase of development across an expanded 900 acres at Port Fourchon on the Gulf of America.
With first LNG deliveries targeted for 2030, Argent LNG is strategically poised to meet skyrocketing global demand for cleaner-burning natural gas while bolstering energy security for U.S. allies. Port Fourchon's unparalleled location delivers the fastest shipping routes to Europe and the Atlantic Basin, slashing delivery times, cutting shipping emissions, and enabling forward-positioned LNG that stabilizes markets and cushions price volatility.
'Our Gastech launch marks a pivotal moment,' said Jonathan Bass, Chairman & CEO of Argent LNG. 'We're showcasing how Phase One will rise on 900 acres of expanded Port Fourchon land — a location that, combined with advanced design and deep local expertise, guarantees unmatched reliability and resilience for global energy markets.'
Innovative, Low-Emission Tank Technology
Argent LNG's design blends proven LNG production technology with GTT's cutting-edge tank systems, new to the U.S. market but battle-tested globally. These tanks are engineered to dramatically reduce boil-off gas, slash emissions, and boost operational efficiency — aligning perfectly with Argent LNG's vision for responsible, forward-looking energy infrastructure.
'In LNG, it's location, location, location — and Port Fourchon delivers all three,' said Bass. 'Inside the port means zero drayage, direct deepwater access, and the fastest routes to key markets. That's not just convenience — it's a critical competitive advantage for reliability, efficiency, and lower emissions.'
Louisiana First, From the Ground Up
Argent LNG's Louisiana First policy ensures local contractors, suppliers, and workforce form the backbone of the project. Partnering early with Galliano-based Grand Isle Shipyard (GIS), the company leverages generations of Louisiana expertise to de-risk construction while maintaining schedule and budget discipline.
This approach will create thousands of jobs across fabrication, engineering, logistics, and support services — while strengthening the long-term economic resilience of Louisiana's coastal parishes.
A Strategic Energy Asset for Allied Nations
By forward-positioning LNG at Port Fourchon, Argent LNG mitigates supply disruptions and market vulnerabilities for key international markets across Europe, East Asia, the Middle East, and South America. This prime location enables rapid, reliable deployment to countries sharing common security and economic interests with the U.S.
Timeline and Technology
By integrating cutting-edge solutions from Baker Hughes, Honeywell UOP, ABB, and GTT, Argent LNG combines proven, state-of-the-art technologies to maximize efficiency, reduce emissions, and ensure world-class reliability for a sustainable energy future. Phase One construction is slated to begin in 2027, featuring modern liquefaction and storage technology designed for efficiency and flexibility. The full buildout will deliver 25 MTPA of LNG capacity, cementing the U.S.'s role as a global leader in secure, responsible energy exports.
'Energy security starts with smart positioning and smarter design,' Bass added. 'Our expanded Port Fourchon site isn't just real estate — it's a launchpad for dependable, efficient, and lower-emission energy supply to the world.'
About Argent LNG
Argent LNG is a next-generation liquefied natural gas exporter committed to delivering reliable, secure, and responsible American energy to global markets. Leveraging Louisiana's energy heritage and innovation, Argent LNG is building the infrastructure needed to support the energy transition and strengthen global partnerships.
jonathan bass
Argent LNG, LLC
email us here
Visit us on social media:
X
Legal Disclaimer:
EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Under Armour expects revenue drop in Q2 FY26 after Q1 loss
US-based sportswear retailer Under Armour has announced its financial results for the first quarter (Q1) of fiscal 2026 (FY26), highlighting a decline in revenue and a cautious outlook for Q2. The company's revenue fell 4% to $1.1bn, with North American revenue down 5% to $670m and international revenue down 1% to $467m. Despite these challenges, Under Armour's gross margin improved 70 basis points to 48.2%, largely attributed to beneficial foreign exchange rates, strategic pricing decisions and an advantageous product mix. This was partially counterbalanced by a less favourable channel mix and an increase in supply chain expenses in comparison to the previous year. Under Armour president and CEO Kevin Plank stated: "We are pleased our quarterly results met or exceeded our expectations as we drive a bold transformation – sharpening Under Armour into a brand where sports credibility, innovation and style meet operational discipline." Direct-to-consumer revenue dropped by 3% to $463m, with e-commerce revenue dip of 12%. Apparel revenue decreased slightly to $747m, footwear revenue saw a significant drop of 14% and accessories revenue grew 8% to $100m. Operating income stood at $3m while adjusted operating income was $24m. The retailer posted a net loss of $3m with adjusted net income of $9m. The company's fiscal 2025 restructuring plan, announced in May 2024, is estimated to cost between $140m and $160m. As of the end of Q1 FY26, Under Armour had recorded $71m in restructuring and impairment charges, along with $39m in other related transformational expenses. The plan is expected to be completed by the end of FY26. Under Armour expects Q2 FY26 revenue to decline by between 6% and 7%, with a low-double-digit percent decrease in North America and a low-teens percent decline in the Asia-Pacific region. Gross margin is projected to decline between 340 and 360 basis points due to supply chain headwinds, including the impact of tariffs. Selling, general and administrative expenses are anticipated to rise, driven by higher marketing investments. Operating income could see a loss of up to $10m or breakeven, with adjusted operating income forecasted to be between $30m and $40m. Diluted loss per share is expected to range from $0.07 to $0.08, with adjusted diluted earnings per share between $0.01 and $0.02. Plank added: "Moving ahead, we're focused on strengthening our brand positioning with premium products and increasing our average selling prices through innovative offerings, optimising our top-volume programmes, and creating a more compelling full, price-to-value proposition. Regardless of the backdrop, this is about building a fearless, thoughtful and stronger Under Armour." "Under Armour expects revenue drop in Q2 FY26 after Q1 loss" was originally created and published by Retail Insight Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
an hour ago
- Yahoo
Nutriband CEO Gareth Sheridan Seeks Nomination in Upcoming Irish Presidential Election
Sheridan will temporarily step aside as CEO to enter the Irish Presidential Election. Company Chairman and President, Serguei Melnik will take over as interim CEO over the course of the campaign and election period. ORLANDO, Fla., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) has announced that Company CEO, Gareth Sheridan will be stepping aside from his role for three months to enter the Irish Presidential election. The Nomination Hearings followed by the Election will take place over the course of September and October. During this period, Co-Founder and Chairman, Serguei Melnik will take over the responsibilities of CEO and guide the company through the final 2025 framework towards the target NDA filing in 2026. Mr. Melnik, a corporate strategy expert will continue to execute the Company's strategic development and focus on shareholder value. Mr. Melnik has over 20 years experience in Capital markets. "I have made the decision to temporarily step aside as CEO following the support and encouragement I have received asking me to put my name forward for the election for President of Ireland. Rest assured, Nutriband is in very safe hands. While most often we talk about AVERSA as our big opportunity, it is our tight knit team that is really our core asset. I look forward to watching Nutriband continue to hit its planned targets between now and December," said Mr. Sheridan. The FDA recently granted Nutriband's meeting request for AVERSA Fentanyl AVERSA FENTANYL has the potential to be the world's first abuse-deterrent opioid patch designed to deter the abuse and misuse and reduce the risk of accidental exposure of transdermal fentanyl patches. AVERSA FENTANYL has the potential to reach peak annual US sales of $80 million to $200 million.1 While initially concentrating on the US market, the unmet medical need for adequate pain management is a global problem, and our goal is to make AVERSA FENTANYL available in all major medical markets in the world. The AVERSA™ abuse deterrent technology is protected by a broad international intellectual property portfolio with patents issued in 46 countries including the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia. ____________________________________________________1 Health Advances Aversa Fentanyl market analysis report 2022 About AVERSA™ Abuse-Deterrent Transdermal Technology Nutriband's AVERSA™ abuse-deterrent transdermal technology incorporates aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential. The AVERSA™ abuse-deterrent technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, such as fentanyl, while making sure that these drugs remain accessible to those patients who really need them. The technology is covered by a broad intellectual property portfolio with patents granted in the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia. About Nutriband Inc. We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse-deterrent fentanyl patch incorporating our AVERSA™ abuse-deterrent technology. AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential. The Company's website is Any material contained in or derived from the Company's websites or any other website is not part of this press release. Forward-Looking Statements Certain statements contained in this press release, including, without limitation, statements containing the words ''believes," "anticipates," "expects" and words of similar import, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company's actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including those including the Company's ability to develop its proposed abuse-deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing, its ability to obtain Federal Food and Drug Administration approval to market any product it may develop in the United States and to obtain any other regulatory approval necessary to market any product in other countries, including countries in Europe, its ability to market any product it may develop, its ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company's business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's Form S-1, Forms 10-K's and Forms 10-Q's, and the Company's other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof. Contact Information: Nutriband 407-377-6695Email: info@ SOURCE: Nutriband in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
2 hours ago
- Associated Press
Nutriband CEO Gareth Sheridan Seeks Nomination in Upcoming Irish Presidential Election
Sheridan will temporarily step aside as CEO to enter the Irish Presidential Election. Company Chairman and President, Serguei Melnik will take over as interim CEO over the course of the campaign and election period. ORLANDO, Fla., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) has announced that Company CEO, Gareth Sheridan will be stepping aside from his role for three months to enter the Irish Presidential election. The Nomination Hearings followed by the Election will take place over the course of September and October. During this period, Co-Founder and Chairman, Serguei Melnik will take over the responsibilities of CEO and guide the company through the final 2025 framework towards the target NDA filing in 2026. Mr. Melnik, a corporate strategy expert will continue to execute the Company's strategic development and focus on shareholder value. Mr. Melnik has over 20 years experience in Capital markets. 'I have made the decision to temporarily step aside as CEO following the support and encouragement I have received asking me to put my name forward for the election for President of Ireland. Rest assured, Nutriband is in very safe hands. While most often we talk about AVERSA as our big opportunity, it is our tight knit team that is really our core asset. I look forward to watching Nutriband continue to hit its planned targets between now and December,' said Mr. Sheridan. The FDA recently granted Nutriband's meeting request for AVERSA Fentanyl AVERSA FENTANYL has the potential to be the world's first abuse-deterrent opioid patch designed to deter the abuse and misuse and reduce the risk of accidental exposure of transdermal fentanyl patches. AVERSA FENTANYL has the potential to reach peak annual US sales of $80 million to $200 million.1 While initially concentrating on the US market, the unmet medical need for adequate pain management is a global problem, and our goal is to make AVERSA FENTANYL available in all major medical markets in the world. The AVERSA™ abuse deterrent technology is protected by a broad international intellectual property portfolio with patents issued in 46 countries including the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia. ____________________________________________________ 1 Health Advances Aversa Fentanyl market analysis report 2022 About AVERSA™ Abuse-Deterrent Transdermal Technology Nutriband's AVERSA™ abuse-deterrent transdermal technology incorporates aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential. The AVERSA™ abuse-deterrent technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, such as fentanyl, while making sure that these drugs remain accessible to those patients who really need them. The technology is covered by a broad intellectual property portfolio with patents granted in the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia. About Nutriband Inc. We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse-deterrent fentanyl patch incorporating our AVERSA™ abuse-deterrent technology. AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential. The Company's website is Any material contained in or derived from the Company's websites or any other website is not part of this press release. Forward-Looking Statements Certain statements contained in this press release, including, without limitation, statements containing the words ''believes,' 'anticipates,' 'expects' and words of similar import, constitute 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company's actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including those including the Company's ability to develop its proposed abuse-deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing, its ability to obtain Federal Food and Drug Administration approval to market any product it may develop in the United States and to obtain any other regulatory approval necessary to market any product in other countries, including countries in Europe, its ability to market any product it may develop, its ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company's business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under 'Risk Factors' and 'Management's Discussion and Analysis of Financial Condition and Results of Operations' in the Company's Form S-1, Forms 10-K's and Forms 10-Q's, and the Company's other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof. Contact Information: Nutriband Inc. Phone: 407-377-6695 Email: [email protected] SOURCE: Nutriband Inc.
